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Osteoarthritis (OA) is a chronic degenerative joint disease of dynamic  pathology 
with multiple etiologies. It involves progressive process of softening, loss of articu-
lar cartilage, subchondral bone sclerosis, development of osteophytes, and cyst 
formation. OA usually contributes to decreased activity associated with aging, 
secondary to diminished function and pain, thus consequently impairing quality 
of life. It is well established that pain due to OA, swelling, or stiffness can make it 
difficult for individuals to perform simple daily living activities. Although OA is 
not curable, a variety of treatment modalities are available to improve symptoms. 
Main elements include pain management maneuvers, education, changing lifestyle 
physical activity (PA), and weight reduction in case of overweight. Although total 
joint arthroplasty (TJA) is considered a cost-effective treatment for people with OA, 
TJA should only be considered after failure of conservative treatments. Symptoms 
of OA are usually managed by either pharmachological or nonpharmachological 
protocols; joint replacement surgeries are considered in advanced cases. Analgesics 
remain the keystone of pharmacological treatment for OA symptoms, including 
paracetamol, topical and oral nonsteroidal anti-inflammatory drugs (NSAIDs), and 
opioids. However, benefits from paracetamol and opioids are minimal, and NSAIDs 
are not ideal for many patients because they have many side-effects. Intra-articular 
therapies such as corticosteroids are also commonly used, though usually with 
short-term benefits.
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1. Introduction
Osteoarthritis (OA) is a chronic degenerative joint disease of dynamic pathol-
ogy with multiple etiologies. It involves progressive process of softening, loss of 
articular cartilage, subchondral bone sclerosis, development of osteophytes, and 
cyst formation [1].
Knee OA is the most common arthritic disease among all joints; however, there 
is no available drug treatment today that hinders the progression of this disease 
process. There are many reasons for this, including the lack of understanding of 
what worsens the disease process and the heterogeneity of the patient population. 
There are considerable differences in the course of the disease [2].
The median age for diagnosis of Knee OA is 55 years, and usually people live 
about 30 years suffering the disease [3].As there is no known curative treatment 
for OA till now, treatments aim at improving function as well as reducing pain. 
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Systematic reviews (SR) are a useful research method to analyze the efficacy of 
knee OA treatments; however, most of these reviews have not discussed the long-
term risks associated with various treatment modalities. The cause for that is most 
studies follow patients for short time periods. There are missing data in the litera-
ture owing to the fact that most of these studies are short-term studies, thus giving 
a false impression about the correct data concerning short-term improvement; 
especially, OA is a chronic condition needing long-term studies to correctly estimate 
the degree of pain improvement.
Approximately 30–65% of the risk of OA is genetically determined [4].
Obesity has long been known as a risk factor for knee OA [3]. A recent meta-
analysis also showed that increased BMI added to the increased risks to radiographic 
and/or clinical OA picture [5].
OA usually contributes to decreased activity associated with aging, secondary 
to diminished function and pain, thus consequently impairing quality of life. It is 
well established that pain due to OA, swelling, or stiffness can make it difficult for 
individuals to perform simple daily living activities [6].
Researches on the role of special diets in OA have been evolving. High dietary 
fiber intake has been associated with lower risk of developing moderate to severe 
knee pain over time. Results from two prospective cohort studies also showed that 
increased total fiber intake was related to lower risk of symptomatic knee OA, but 
its association with radiographic knee OA is still not evident [7]. Another study 
found that increased soy milk intake was associated adversely with prevalence of 
radiographic knee osteophytes [8]. Finally, higher intake of Mediterranean diet was 
associated with lower prevalence of radiographic and clinical KOA [9].
The patient usually experiences knee pain and any three of the following to diag-
nose clinical OA of the knee: [1] tenderness on one or more knee compartments; 
[2] crepitus on active motion in at one or more knee compartments; [3] morning 
stiffness usually less than 30 minutes, according to WOMAC scale; [4] no warmth 
on knee examination; [3] age more than 50 years; or [5] osteophytes in one or more 
knee compartments [10].
Although OA is not curable, a variety of treatment modalities are available to 
improve symptoms. Main elements include pain management maneuvers, educa-
tion, changing lifestyle physical activity (PA), and weight reduction in case of 
overweight. Although total joint arthroplasty (TJA) is considered a cost-effective 
treatment for people with OA, TJA should only be considered after failure of 
conservative treatments. Since OA is a chronic disease, a key element in the non-
surgical management of knee and/or hip OA is self-management. Self-management 
interventions allow patients to improve their skills in taking care of themselves and 
to improve skills to navigate the health care system [11].
The shape of the bone may add to the risk of OA as had been described primarily 
in the hip joint. The association between OA and muscle strength may vary depend-
ing on the muscles and joints being studied. In an examination of anterior cruciate 
ligament (ACL) injured knees, high thigh muscle cross-sectional area and high 
muscle/fat ratio had a protective effect against KOA prevalence. Deformities of the 
knee are a strong predictor of knee OA disease progression [12].
Health education should be considered as a basic element of effective self-
management interventions. Health education should include education about OA 
and its treatment options, exercise and pacing of PA, and weight reduction. This 
information should be tailored to the person’s illness perception and educational 
capability. In addition, goal setting is a widely used behavioral change technique 
in many fields, especially in health care. Goal setting is associated with positive 
impact on behavior at both shorter and longer terms [13]. Behavioral monitoring of 
outcomes (e.g. amount of PA, weight and achievement of goals).
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Symptoms of OA are usually managed by either pharmachological or nonphar-
machological protocols; joint replacement surgeries are considered in advanced 
cases. Analgesics remain the keystone of pharmacological treatment for OA 
symptoms, including paracetamol, topical and oral nonsteroidal anti-inflammatory 
drugs (NSAIDs), and opioids. However, benefits from paracetamol and opioids 
are minimal, and NSAIDs are not ideal for many patients because they have many 
side-effects. Intra-articular therapies such as corticosteroids are also commonly 
used, though usually with short-term benefits. Pharmacological drugs include the 
following.
1.1 Colchicine
It is usually used for the treatment of pseudogout and gout. Colchicine is not 
recommended for treatment of OA nowadays. Synovial fluid in OA usually contains 
basic calcium phosphate (BCP) crystals especially hydroxyapatite crystals (detected 
in the cartilage of nearly all affected joints at the time of joint replacement surger-
ies). Positive correlations have been found between synovial fluid BCP crystal levels 
and radiographic severity of OA [14].
1.2 Hydroxychloroquine
Hydroxychloroquine has been used in in patients with inflammatory OA of hand 
joints with some suggested evidence of benefits, probably because it may have a role 
in treating rheumatoid arthritis (RA) synovitis and an acceptable safety profile. It 
has immunomodulatory effects and was considered to potentially treat OA due to 
Toll-like receptor (TLR) signaling inhibition, as TLRs are upregulated in OA carti-
lage and may have a role in cartilage breakdown via proinflammatory pathways [15].
A mixture of pharmacologic and nonpharmacologic therapies can manage OA 
symptoms as there is currently no available disease-modifying therapy till now, 
so treatment depends on symptomatic slow-acting drugs for OA (SYSADOAs) as 
an important category in the pharmacologic therapy tools for OA that have been 
demonstrated to alleviate the symptoms of functional impairment and pain, with 
some additional evidence of a disease-modifying effect on the long run [16]. The 
SYSADOAs class comprises different elements, including chondroitin, glucosamine, 
diacerein, and avocado soybean unsaponifiables (ASU), and there are some clinical 
data supporting their efficiency. Placebo-controlled trials of SYSADOAs treatment 
lasting up to 3 years in more than one Meta-analyses provide evidence that pre-
scribing grade crystalline glucosamine sulfate (GS), chondroitin sulfate (CS), and 
diacerein has mild to moderate benefits in patients with OA [17].
Numerous meta-analyses and RCTs have been conducted to assess the efficacy 
and safety of Intra-articular hyaluronic acid (IAHA), with mixed results and 
conclusions support the fact that IAHA injection is considered a suitable alternative 
local treatment option providing symptomatic benefit without the systemic adverse 
effects that may be associated with IA corticosteroids. IAHA is considered to have a 
positive effect on pain and joint function. A meta-analysis comparing the effective-
ness of pharmacological interventions for knee OA found that IAHA is considered 
an effective therapy. IAHA is also demonstrated to have a longer lasting effect on 
function and pain compared with IA corticosteroids, lasting up to 6 months [18].
Multiple courses of IAHA can cause long-term beneficial outcomes, including 
reduction in analgesics used and delay in the need for joint replacement surgeries 
[19] still found regarding the risk benefit of IAHA. However, controversy about 
lack of agreement among international guidelines regarding the use of IAHA for the 
management of symptomatic knee OA still exists [20].
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The safety of IAHA has been evaluated in eight meta-analyses of RCTs com-
paring IAHA to IA placebo. However, a Cochrane review of 76 RCTs was unable 
to conclude a definitive report on the safety of HA due to limitations concerning 
sample size; however, no major safety issues were found, in addition, IAHA demon-
strated similar efficacy to systemic forms of medical interventions, with more local 
reactions but fewer systemic adverse effects [21].
Evidence suggests that exercise is one of the core therapies for OA to improve 
function and pain. The degree of response varies according to the type of exercise 
(e.g. aerobic, strengthening, etc.). Little is known about the relative effeciency of 
different exercise forms [22].
The comparisons were seen between strengthening exercises and mixed exer-
cises versus usual care. For pain, function, and performance, all types of exercise 
were significantly better than usual care. The largest effect was observed for aerobic 
and mind-body exercises for function and pain. Strengthening and flexibility 
exercises had a moderate score, whereas mixed exercise gave the minimum score for 
all outcomes and was significantly less effective than aerobic or mind-body exercise 
for pain. The ranking mainly corresponded to the magnitude of the score shown by 
each exercise. Aerobic exercises were the best-ranked for performance and pain, 
whereas mind-body was also the best-ranked for self-reported pain and function. 
Strengthening and flexibility/skill generally received mid-level rankings while 
mixed exercises were the least ranked exercise [23].
It is confirmed that exercise is still important for people suffering from hip and 
knee OA for outcomes of performance function, pain. In additon, it was found that 
mind-body and aerobic exercise have the largest score for improvements in function 
and pain; strengthening and flexibility exercises improve multiple outcomes to a 
varying degree [23]. Older age is a well-known risk factor for OA; women are more 
likely to develop hand, foot, and knee OA compared to men [4].
Varus thrust increased the odds of worsening medial bone marrow lesions 
(BMLs) and medial cartilage loss as well as the odds of incident medial BMLs of the 
knee among those with KOA and those with increased risk of Knee OA according to 
the Multicenter Osteoarthritis Study (MOST) [24].
It was found that aerobic exercises have similar effects to mind-body exercises 
for controlling pain. Mind-body exercise such as yoga and tai chi can be character-
ized as mild to moderate intensity exercise performed with an intentional awareness 
(mindfulness) on breathing and slow controlled movement [25]. Although the 
underlying mechanism is not clear, the effect of both mind-body and aerobic exer-
cises may be related to the possibility that these exercises affect the altered central 
nervous system such as central pain sensitization, mood disorders, and sleep dis-
turbance. Pain experience is the result of interactions between these central failure 
and peripheral pain mechanisms, as aerobic and mind-body exercise can influence 
both central and peripheral pain mechanisms. There is no satisfactory explanation 
for the poor effect of mixed exercise, particularly when considering that there are 
many domains of physical impairment in people with OA [23].
So far, NSAIDs, symptomatic slow-acting drugs for OA, analgesics, bone-acting 
agents, putative disease-modifying agents, and agents for intra-articular injec-
tion including HA and corticosteroids have been used as pharmacological agents 
for treating OA. However, it has been reported that these agents are not efficient 
against the main cause of OA, may cause some side effects, and are not adequate 
for the long-term management of OA. NSAIDs are the most commonly used drugs 
for the management of OA. They showed moderate improvement against OA pain; 
however, it is advised that NSAIDs be used intermittently and not advised for longer 
periods. NSAIDs can be classified as cyclooxygenase-2 selective agents and nonse-
lective agents [26].
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2. Putative disease-modifying agents
Putative disease-modifying drugs for OA like doxycycline, sprifermin, and cin-
dunistat have not proved significant improvements of the joint so far although the 
clinical trials conducted to prove the effect of these drugs are still under trial [18].
3. Bone-acting agents
Bone-forming agents or antiresorptive agents like zoledronic acid, risedronate, 
strontium ranelate, calcitonin, and vitamin D are classified as bone-acting agents 
for the management of OA. They are bone-acting agents that showed some recorded 
effect in the turnover of subchondral bone, although these agents did not show a 
significant improvement in the structure of the joint [26].
4. Agents for intra-articular injection
Agents for intra-articular injection include HA and corticosteroids like triam-
cinolone, betamethasone, and methylprednisolone. Intra-articular injection of 
corticosteroids showed a greater beneficial effect. Furthermore, during follow-up 
periods of 3 and 6 months, intra-articular injection of HA showed a better thera-
peutic effect. Intra-articular injection of a combination of HA and corticosteroids 
showed a moderate beneficial effect on the pathological process of OA. However, 
for long-term pain control, intra-articular injection of HA did not show a signifi-
cant improvement [26].
Use of nonpharmacological modalities (e.g. exercise) as a first-line management 
for knee OA is little to be compared with pharmacological modalities and usually 
associated with higher rates of surgical interventions. The results indicate that 
nonpharmacological agents such as exercise and weight reduction are effective in 
management of knee OA with minimal adverse side effects. Therefore, exercise 
and weight reduction should be advised as part of the treatment in most patients 
owing to their minimal side effects and cost effectiveness, as well as associated 
health benefits. It is important to specify resources and invest in supporting general 
practitioners and other primary health care providers to provide lifestyle interven-
tions as a tool in managing knee OA [27].
Irrespective of a large body of evidence concerning the benefits of their use, 
opiates are used to manage pain associated with Knee OA. No studies fulfilled the 
inclusion criteria as the follow-up periods of these studies concerning safety were 
less than 6 months. A recent systematic review of chronic pain management found 
that there is insufficient evidence to support the effectiveness of long-term opioid 
therapy [28]. Opioids provide effective analgesia; however, benefits are usually 
encountered by frequent side effects such as nausea (30%), dizziness (20%), vomit-
ing (13%), constipation (23%), and somnolence (18%) as well as the risk of addic-
tion increases on chronic opioid use. The evidence on the safety and effectiveness of 
long-term opioid therapy for Knee OA cannot be evaluated. This is a concern and a 
limitation of the available evidence related to management of Knee OA. In the USA, 
there has been a significant increase in opioid prescriptions for patients suffering 
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